Research map: RRx-001 induces apoptosis through reactive oxygen species and endoplasmic reticulum stress in Burkitt lymphoma cells by acting as CD47 and c-Myc regulator

Back to the article

Papers in this map

  1. ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage · Shuhei Matsuoka · 2007 · 3145 citations · Cited by this paper
  2. Small-molecule LIFR inhibitors attenuate renal tubulointerstitial fibrosis · 2026 · Related
  3. Burkitt's lymphoma · ELIZABETH M. MOLYNEUX · 2012 · 619 citations · Cited by this paper
  4. Indole-3-carbaldehyde mitigates fibrosis progression in MASH with T2DM via the SIRT1/TGF-β/SMAD signaling pathway · 2026 · Related
  5. MYC as a target for cancer treatment · Michael Joe Duffy · 2021 · 560 citations · Cited by this paper
  6. Microbial influence on tryptophan metabolism in tumors:Mechanisms and potential clinical applications · 2026 · Related
  7. The MYC oncogene is a global regulator of the immune response · Stephanie C. Casey · 2018 · 280 citations · Cited by this paper
  8. HACD1-driven long-chain fatty acid metabolic reprogramming enhances esophageal cancer tumorigenicity · 2026 · Related
  9. Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress · Shan Yan · 2014 · 254 citations · Cited by this paper
  10. TNFAIP1 as a novel therapeutic target in ulcerative colitis and salidroside as its potential inhibitor · 2026 · Related
  11. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy · Xiao Jia · 2021 · 203 citations · Cited by this paper
  12. EGR2 promotes vascular smooth muscle cell differentiation and proliferation in outward remodeling during arteriovenous fistula maturation · 2026 · Related
  13. Reactive oxygen species and DNA damage response in cancer · Xavier Renaudin · 2021 · 161 citations · Cited by this paper
  14. Targeting 15-PGDH/15-oxoETE to mitigate inflammation and senescence in asthma · 2026 · Related
  15. Chaetocin-induced ROS-mediated apoptosis involves ATM–YAP1 axis and JNK-dependent inhibition of glucose metabolism · Deobrat Dixit · 2014 · 100 citations · Cited by this paper
  16. The irisin-PINK1/Parkin axis plays an essential role in mediating microglial mitophagy: A crucial mechanism for exercise-induced neuroprotection against Parkinson's disease · 2026 · Related
  17. AIF-mediated caspase-independent necroptosis requires ATM and DNA-PK-induced histone H2AX Ser139 phosphorylation · Mathieu Baritaud · 2012 · 94 citations · Cited by this paper
  18. tRNA-derived fragment tRF-17-8SPOL52 induces resistance to bortezomib in multiple myeloma via autophagy activation · 2026 · Related
  19. RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages · Pedro Cabrales · 2019 · 93 citations · Cited by this paper
  20. Just eat it: A review of CD47 and SIRP-α antagonism · Bryan T. Oronsky · 2020 · 90 citations · Cited by this paper
  21. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells · Deepika Sharma Das · 2016 · 85 citations · Cited by this paper
  22. ROS and Endoplasmic Reticulum Stress in Pulmonary Disease · Xiangning Cui · 2022 · 61 citations · Cited by this paper
  23. REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer · Bryan T. Oronsky · 2019 · 55 citations · Cited by this paper
  24. The CD47-SIRPα axis is a promising target for cancer immunotherapies · Yu Hao · 2023 · 53 citations · Cited by this paper
  25. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development · Bryan T. Oronsky · 2021 · 48 citations · Cited by this paper
  26. Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis · Shuai Ren · 2021 · 46 citations · Cited by this paper
  27. Correction to: Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review · Juan Du · 2020 · 29 citations · Cited by this paper
  28. Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells · Bryan T. Oronsky · 2018 · 23 citations · Cited by this paper
  29. RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic" · Bryan T. Oronsky · 2020 · 22 citations · Cited by this paper
  30. PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy · Marcelo Raul Bonomi · 2023 · 20 citations · Cited by this paper
  31. Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet · Vincent Ribrag · 2025 · 19 citations · Cited by this paper
  32. Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy · Pengcheng Zhao · 2023 · 17 citations · Cited by this paper
  33. CD47 as a potent target in cancer immunotherapy: A review · Hiva Ahvati · 2025 · 17 citations · Cited by this paper
  34. Novel immunotherapy for gastric cancer: targeting the CD47–SIRPα axis · Akira Ooki · 2025 · 16 citations · Cited by this paper
  35. RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia · Bryan T. Oronsky · 2021 · 15 citations · Cited by this paper
  36. Global, regional, and national burden of Burkitt lymphoma from 1990 to 2021 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2021 · Ying Wang · 2024 · 15 citations · Cited by this paper
  37. The Physiological and Therapeutic Role of CD47 in Macrophage Function and Cancer · Shelby N. Bess · 2024 · 13 citations · Cited by this paper
  38. Promotion of triple negative breast cancer immunotherapy by combining bioactive radicals with immune checkpoint blockade · Meixu Chen · 2025 · 12 citations · Cited by this paper
  39. A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma · Howard Alan Fine · 2023 · 11 citations · Cited by this paper

Source: OpenAlex (CC0)